Evidence map›Paper›PMID 39859045›Full record

ArticleMedicina (Kaunas, Lithuania)2025

Meropenem Continuous Infusion in a Septic Patient with Periprosthetic Infection and End-Stage Renal Disease Undergoing Prolonged Intermittent Renal Replacement Therapy.

Assiya Kadralinova, Maiya Konkayeva, Serik Dzhandayev, Aidos Konkayev

Abstract readCase Reports
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Assiya KadralinovaDepartment of Anesthesiology and Intensive Care, Astana Medical University, Astana 010000, Kazakhstan.ORCID 0000-0001-6702-657X
Maiya KonkayevaDepartment of Anesthesiology and Intensive Care, National Scientific Center of Traumatology and Orthopedics Named After Academician N.D. Batpenov, Astana 010000, Kazakhstan.
Serik DzhandayevDepartment of Ear, Nose, Throat Diseases, Astana Medical University, Astana 010000, Kazakhstan.
Aidos KonkayevDepartment of Anesthesiology and Intensive Care, Astana Medical University, Astana 010000, Kazakhstan.ORCID 0000-0002-3778-7877

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This case report highlights the use of continuous infusion of meropenem in a 42-year-old septic female patient with periprosthetic infection and end-stage renal disease receiving prolonged intermittent renal replacement therapy (PIRRT). Antibiotic infusion in patients receiving renal replacement therapy has its own peculiarities. There are many studies on the optimal dosing regimen for meropenem in renal dysfunction, but studies on the optimal infusion duration in these patients are limited. The patient was admitted with complaints of wounds, necrosis zones of the right upper limb, restriction of joint movements, and temperature increase up to 38 °C. The patient was treated with a continuous infusion of meropenem 2 g per day receiving renal replacement therapy three times a week (12 h). Also during hospitalization, the patient underwent hip disarticulation and excision of necrotic tissues. The patient was further transferred to a specialized nephrology department for further treatment. We believe that in this clinical case, the use of continuous infusion of meropenem in the complex therapy of sepsis in a patient with CKD undergoing PIRRT sessions helped to lead to clinical improvement in the patient. Further studies are needed.

Indexed as

Anti-Bacterial AgentsKidney Failure, ChronicMeropenemProsthesis-Related InfectionsRenal Replacement TherapySepsisAdultFemaleHumansInfusions, IntravenousAnti-Bacterial AgentsMeropenemcase reportend-stage kidney diseaseinfectionmeropenem continuous infusionPIRRTsepsis

Identifiers

PMID39859045
PMCPMC11766907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.